首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Cxcl17 |
| Uniprot No | Q6UXB2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-119aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MSSLNPGVAR GHRDRGQASR RWLQEGGQEC ECKDWFLRAP RRKFMTVSGL PKKQCPCDHF KGNVKKTRHQ RHHRKPNKHS RACQQFLKQC QLRSFALPL |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Cxcl17重组蛋白的3篇代表性文献的简要概述(基于真实研究方向的模拟示例，供参考)：
---
1. **文献名称**：CXCL17 is a mucosal chemokine elevated in idiopathic pulmonary fibrosis that exhibits broad antimicrobial activity
**作者**：Shigehara, K. et al.
**摘要**：该研究利用重组CXCL17蛋白，揭示了其在呼吸道黏膜免疫中的双重功能：通过趋化单核细胞/树突状细胞参与免疫调控，并表现出广谱抗菌活性，可能作为先天防御分子。
2. **文献名称**：CXCL17 is a major chemokine for recruiting macrophages in ovarian cancer microenvironment
**作者**：Lee, A.Y. et al.
**摘要**：通过重组CXCL17蛋白的体外实验，发现其能显著诱导巨噬细胞迁移，并在卵巢癌模型中证实肿瘤源性CXCL17通过募集TAMs(肿瘤相关巨噬细胞)促进肿瘤进展。
3. **文献名称**：Structural and functional characterization of human CXCL17 as a ligand for Chemokine Receptor DARC
**作者**：Nomiyama, H. et al.
**摘要**：研究通过重组CXCL17蛋白解析其与受体DARC的相互作用机制，揭示了CXCL17独特的结构域对其趋化功能及炎症调节的关键作用。
---
**备注**：以上文献为示例性质，实际引用时建议通过PubMed、Google Scholar等平台以关键词“CXCL17 recombinant”或“CXCL17 function”检索最新文献。部分研究可能涉及重组蛋白的生产、功能验证或治疗应用，具体需结合研究方向筛选。
CXC chemokine ligand 17 (CXCL17) is a member of the chemokine family, a group of small secreted proteins that regulate immune cell migration and activation. Discovered relatively recently compared to other chemokines, CXCL17 is classified within the CXC subfamily due to the presence of a conserved N-terminal cysteine motif. It is primarily expressed in mucosal tissues, including the respiratory and gastrointestinal tracts, and has been implicated in both homeostatic immune surveillance and pathological conditions such as inflammation, cancer, and infectious diseases. Unlike many chemokines, CXCL17 lacks a classic receptor-binding ELR motif and does not signal through traditional chemokine receptors like CXCR1-6. making its receptor interactions and signaling mechanisms distinct and not yet fully characterized.
Recombinant CXCL17 protein is produced using genetic engineering techniques, typically through expression in prokaryotic (e.g., E. coli) or eukaryotic (e.g., mammalian or insect) systems, followed by purification to ensure bioactivity. This engineered protein retains the functional properties of native CXCL17. including chemoattractant activity for dendritic cells, macrophages, and endothelial cells. Structurally, CXCL17 contains a conserved chemokine domain and a unique C-terminal extension rich in proline residues, which may contribute to its interaction with glycosaminoglycans or extracellular matrix components.
Research on recombinant CXCL17 has highlighted its dual roles in health and disease. It supports mucosal immunity by recruiting innate immune cells to barrier tissues but is also overexpressed in certain cancers, where it may promote angiogenesis or immunosuppression. Its involvement in chronic inflammatory diseases, such as asthma and colitis, further underscores its therapeutic relevance. However, conflicting studies report both pro- and anti-tumor effects, suggesting context-dependent functionality. Current studies focus on clarifying its receptor interactions, structural determinants, and therapeutic potential as a biomarker or immunomodulatory target. Recombinant CXCL17 remains a critical tool for dissecting its complex biology and translational applications.
×
